MMED shares climbed roughly 15.4% over the last 30 days, from a closing price of $16.93 on July 17, 2026, to $19.53 at the latest available close. The advance was supported by expanded U.S. Medicare access to the MiniMed Flex system, the start of commercial U.S. shipments with Abbott's Instinct sensor, and favorable analyst actions.
NNNN rallied +39.10% to $12.38 in early regular trading Monday, extending a premarket gain of roughly +18%. The advance occurred during normal market hours, with NNNN opening near $12.00 and touching a $12.64 session high.
Selected target: $20 per share, roughly 44% above Avantor's recent price near $13.93 and above the highest current Street target of $19. Strongest bullish factors: a second-quarter earnings beat, raised fiscal 2026 adjusted EPS guidance, cost-savings turnaround efforts, a $500 million buyback authorization, and expansion in high-purity silicone applications.
Revenue: Net sales reached $2.78 billion, up 8% year-over-year and modestly ahead of the $2.77 billion consensus estimate. Core EPS: Core diluted earnings per share (EPS) came in at $0.84, beating analyst expectations of approximately $0.76–$0.77 by roughly 9–11%.
Price Target: $25 represents a roughly 27.5% upside from the current price near $19.60 and sits at the top of Wall Street's 12-month analyst target range. Bull Case: Multiple prominent firms — including BTIG, UBS, and Wells Fargo — have assigned price targets at or above $25, citing double-digit revenue growth, expanding margins, and a rapidly growing $18 billion global diabetes technology market.
Alcon (ALC) is scheduled to report second-quarter 2026 earnings on Monday, August 10, after the market close, followed by a conference call on Tuesday morning. Wall Street consensus projects core earnings per share (EPS) of approximately $0.75 to $0.77 on revenue of roughly $2.77 billion , implying modest year-over-year EPS growth and a roughly 7% revenue increase.
LMAT plunged -24.28% during Wednesday's regular session, extending an after-hours selloff that began Tuesday evening following the company's Q2 2026 earnings release after the close. Q2 2026 results missed consensus: adjusted EPS of $0.74 versus the $0.81 estimate, and revenue of $70.38M versus the $71.47M forecast, despite 10% organic sales growth year-over-year.
MDLN shares fell -11.67% during regular trading on Wednesday after the company reported Q2 2026 earnings that revealed a 58.3% year-over-year drop in net income to $139 million. The steep profit decline was driven by $336 million in losses from a fire that destroyed its 1-million-square-foot distribution center in Tracy, California, before expected insurance recoveries.
Intuitive Surgical shares dropped approximately 15% over the past 30 days, accelerating sharply after the company's second-quarter 2026 earnings report released on July 16. Q2 revenue rose 19% year-over-year to $2.89 billion and adjusted EPS of $2.80 beat Wall Street estimates, yet investors focused on unchanged full-year procedure growth guidance.
STAA shares fell -11.42% during Monday's regular session to $23.42, extending Friday's -8.76% rout for a combined two-day decline of roughly -19%. The sell-off originated from Thursday's preliminary Q2 revenue announcement, which beat estimates at $90M+ but lacked any second-half 2026 guidance, sparking analyst caution.
ISRG plunged -11.24% to $357.10 after reporting Q2 results Thursday post-close, with the selloff accelerating through after-hours, premarket, and into Friday's regular session. Despite beating Q2 estimates—EPS of $2.80 vs. $2.51 consensus and revenue of $2.89B vs. $2.82B—the stock was crushed by disappointing forward guidance.
Q2 2026 revenue reached $2.89 billion, up 19% year over year and above consensus estimates. Non-GAAP diluted EPS of $2.80 beat analyst expectations by approximately $0.32 to $0.39.
Medline shares surged approximately 29.2% over the past 30 days, rebounding sharply from a 52-week low of $32.82 reached on June 3, 2026. The recovery was fueled by easing selling pressure after a large secondary offering closed in late May, combined with analyst reaffirmations of bullish ratings despite near-term headwinds.
Anbio Biotechnology (NNNN) shares fell approximately 25% in today’s session. The decline follows the company’s recent IPO and elevated trading levels in prior sessions.
Second quarter 2026 revenue reached a record $1.082 billion, rising 8% year-over-year and 5% organically. Non-GAAP diluted EPS of $1.21 exceeded consensus estimates of $1.10, marking the tenth consecutive quarter of outperformance.
MDLN stock declined approximately 22% over the past 30 days amid post-IPO volatility and broader market pressures in the healthcare sector. Over the past quarter, the stock fell roughly 23%, reflecting sustained selling pressure following the company's initial public offering and mixed financial results.
AZTA shares plunged 23.82% to close at $18.75 from the previous close of $24.61. Primary catalyst: Q2 fiscal 2026 earnings miss, with revenue of $145 million missing estimates of $148.75 million and non-GAAP EPS loss of $0.04 versus expected $0.11 profit.
EMBC shares plunged 54.29% to close at $4.23 from the previous close of $9.25. Primary catalyst: Q2 fiscal 2026 earnings miss with revenue of $221.8 million versus consensus of $235.7 million, and adjusted EPS of $0.27 missing $0.42 estimate.
As we conclude the second quarter of 2025, the final week marks a critical earnings period for investors, with nine companies across diverse sectors reporting their Q1 2025 results during June 30 - July 4, 2025.
In this article, we delve into the recent performance of AI trading bots, particularly those accessible at "Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)," which demonstrated their prowess by generating a notable +5.10% gain while trading BNGO over the past week.